O risco de probmas musculares pode ser maior o SUPRALIP 145 mg for administrado em simultaneo com medicamentos para baixar o colesterol chamados de "estatinas" (tais como a simvastatina, atorvastatina, pravastatina, rosuvastatina or fluvastatina) Avise o seu medico se esta a tomar algum destes medicamentos.
O risco de ruptura dos músculos é maior nalguns doentes. Informs you where you are in the situation of your situation.
Do not take Supralip if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Supralip.
Your doctor may have a blood test to check your muscles before and after starting treatment. The risk of muscle breakdown is higher in some patients. In particular, tell your doctor if: you are over 70 years old you have kidney problems have have have have have have are are are are are are taking drugs called statins to lower cholesterol (such as simvastatin, atorvastatin, pravastatin, rosuvastatin or fluvastatin) have have had (((((((((((((((.
allergic reaction - the signs may include swelling of the face, lips, tongue or throat, which may cause difficulty in breathing yellowing of the skin and whites of the eyes (jaundice), or an increase in liver enzymes - these may be signs of an inflamed liver (hepatitis).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report directly through the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
• As appropriate, all other significant and life-threatening adverse reactions and interactions, especially those related to drugs, tests, foods, and behaviors mentioned above.
SUPRALIP® 160mg FILM-COATED TABLETS (fenofibrate) This medicine is available in the following leaflet. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, or pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It can harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. What is in this leaflet: 1. What Supralip 160mg is and what it is used for 2. What you need to know before you take Supralip 160mg 3. How to take Supralip 160mg 4. Possible side effects 5. How to store Supralip 160mg 6 1. WHAT SUPRALIP 160mg is USED FOR Supralip 160mg belongs to a group of medicines, commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example, the fats known as triglycerides. Supralip 160mg is used along with low-fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood. Supralip 160mg can be used in addition to other medicines (statins) in certain circumstances when levels of the blood are not controlled with a statin alone 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SUPRALIP 160mg Do not take Supralip 160mg if: • you are allergic to fenofibrate or any of the other ingredients of this medicine • you are allergic to peanut or arachis oil or soy lecithin or related products • while taking other medicines ( such as other fibrates or an anti-inflammatory medicine called 'ketoprofen'), you have had an allergic reaction or skin damage sunlight or UV light • you have severe liver kidney or gallbladder problems • you have pancreatitis (an inflamed pancreas which causes abdominal pain) which is not caused by high levels of fat Do not take Suprilip 160mg if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Supralip 160mg. Warnings and Precautions 160mg if: • you have any liver or kidney problems • you may have an inflamed liver (hepatitis) - signs include yellowing of the skin and the whites of the eyes (jaundice ), an increase in liver enzymes (shown in blood tests), stomach pain and itching • you have an under-active thyroid gland (hypo-thyroidism), talk to you your doctor or pharmacist before taking Supralip 160mg. Supralip 160mg and effects on muscles Stop taking Supralip 160mg and see a doctor straight away if you get - unexplained cramps - painful, tender or weak muscles. This is because this medicine can cause serious problems. These problems are rare but include muscle inflammation and breakdown. This can cause kidney damage or even death. Your doctor may have a blood test to check your muscles before and after starting treatment. The risk of muscle breakdown is higher in some patients. In particular, tell your doctor if: • you are over 70 years old • you have kidney problems • you have thyroid problems • you have a close family member These medications are called statins to lower cholesterol (such as simvastatin, atorvastatin, pravastatin, rosuvastatin, or fluvastatin) • you have had had problems with statins or fibrates (such as fenofibrate, bezafibrate or gemfibrozil). If you are not sure, talk to your doctor before taking Supralip 160mg. Other medicines and Supralip 160mg Tell your doctor or pharmacist if you are taking, or have taken any other medicines. In particular: • Anti-coagulants to thin your blood (such as warfarin) • Other medicines to control levels of fat in the blood (such as, statins or fibrates). This drug can be used in combination with other drugs to increase the risk of muscle damage. • cyclosporin (an immunosuppressant) • cyclosporin (an immunosuppressant) If any of the above apply you (or you are not sure), talk to your doctor or pharmacist before taking Supralip 160mg. Pregnancy, breast-feeding and fertility • Tell your doctor if you are pregnant, you may be pregnant or have a baby. This is because Supralip 160mg can affect your unborn baby. You should only use Supralip 160mg if your doctor tells you to. • Do not use Supralip 160mg if you are breast-feeding or planning to breast-feed your baby. This is because it is used in the treatment of cancer. Supralip 160mg contains lactose monohydrate, sucrose and soya oil - Supralip 160mg contains sugars called lactose monohydrate. If you have been told by your doctor that you can not tolerate or digest some sugars, talk to your doctor before taking this medicine. - Supralip 160mg contains soy oil. If you are allergic to peanuts, arachis oil or soy, do not take this medicine. 3. HOW TO TAKE SUPRALIP 160mg Always take this medicine exactly as you or as a doctor. Check with your doctor or pharmacist if you are not sure. Your doctor will determine the appropriate strength for you, depending on your condition, your current treatment and your personal risk status. Take this medicine Take the tablet with food - it will not work if your stomach is empty. - Swallow the tablet with a glass of water. - Do not crush or chew the tablet. Remember that it is more important than 160mg it is important that you: - have a low fat diet - take regular exercise. How much to take The recommended dose is one tablet a day. You are already taking one capsule of Lipantil Micro 200 mg, you can change to one tablet of Supralip 160mg. You will still receive the same amount of medicine.
This product is manufactured by Laboratoires Fournier SA, 42 Longvic Street 21300, Chenove, France and Delta Pharma (Europe) Ltd., 1 Colonial Way, PO Box 233, North Watford, Herts WD24 4EW and repackaged by OPD Laboratories Ltd., Watford, Herts WD24 4PR. Leaflet revision and issue date (Ref.) 07/11/2017. Supralip is a registered Trade Mark of BGP Products Operations GmbH, Switzerland.
During clinical trials, 10% of patients had a creatinine increase of baseline greater than 30 μmol / L with co-administered fenofibrate and simvastatin versus 4.4% with statin monotherapy. 0.3% of patients receiving co-administration had clinically relevant increases in creatinine to> 200 μmol / L.
Muscle toxicity, including rare cases of rhabdomyolysis, with or without renal failure, has been reported with administration of fibrates and other lipid-lowering agents. The incidence of this disorder increases in case of hypoalbuminaemia and previous renal insufficiency. Patients with pre-disposing factors for myopathy and / or rhabdomyolysis, including age above 70 years, or familial history of hereditary muscular disorders, renal impairment, hypothyroidism and high alcohol intake, may be an increased risk of developing rhabdomyolysis. For these patients, the putative benefits and risks of fenofibrate therapy should be carefully weighed up.
Supralip 160 mg is a film-coated tablet containing 160 mg of micronised fenofibrate and is suprabioavailable (larger bioavailability) compared to the previous formulations.
Cytochrome P450 enzymes: In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentration.
Pancreas: Pancreatitis has been reported in patients taking fenofibrate (see sections 4.3 and 4.8). This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation, resulting in obstruction of the common bile duct.
Along with their useful effects, they can not be used without any experience. The table below contains some of the ones associated with fenofibrate. The best place to find a full list of the side effects that can be associated with your medicine, is from the manufacturer's printed information leaflet supplied with the medicine. Alternatively, you can find an example of a manufacturer's information leaflet in the following section. Speak with your doctor or pharmacist if any of the following continues or become troublesome.
If you are having an operation or dental treatment, tell the person carrying out the treatment which you are taking.
Never take more than the prescribed dose. If you suspect that you or someone else might have taken an overdose of this medicine, go to the accident and emergency department of your local hospital. Take the container with you, even if it is empty.
Účinky kterıch léků může přípravek SUPRELIP ovlivnit? Přípravek SUPRELIP může zesílit účinky látek zvýšenou krvácivostí krevní srážlivost, což se projeví. Může zesílit i účinek fenylbutazonu a účinek tzv. perorálních antidiabetik, tj. neinzulínových přípravků, používaných při cukrovce ke snižování hladiny krevního cukru. Při kombinaci s látkami, které samy mohou působit nepříznivě na jaterní funkce (návrobnosti), návrobných zárních závodných závodných závodných zární zární zární zárních. Obecně nedoporučuje kombinovat toto léčivo se statiny (skupina léčiv užívaných rovněž při léčbě hyperlipidemia - např Lovastatin, simvastatin). Existuje zde riziko výskytu toxického účinku na svaly, zejmena v případě již existujícího onemocnění svalů. Sledovány musejí byt také ledvinné funkce při souběžném podávání fenofibrátu a cyklosporinu (přípravku používaného k potlační imunitní (obranné) reakce), protoženénékéném.
Při léčbě přípravkem SUPRELIP I nutné pokračovat v dietě, kterou Vám lékař doporučil. Během léčby muse podrobovat pravidelným lékařským kontrolám a děděrům krve v intervalech, které určí lékař. Přípravek obsahuje sacharosu, a proto by ho neměly užívat osoby se vzácně se vyskytujícími poruchami metabolizmu cukrů (Nesnášenlivost fruktosy, poruchy vstřebáváná glu.
Do you know where you are going to be? V těhotenství se přípravek SUPRELIP užívat nesmí. Otěhotní-li žena v průběhu léčby, I do not know what to do. V období kojení be rovněž přípravek užívat nesmí.
Músculo: Têm sido referidas situações de toxicidade muscular, com ou sem insuficiência renal, incluindo casos muito raros de rabdomiólise, com a administração de fibratos e outros hipolipidemiantes. A incidência destes distúrbios aumenta em situações of hipoalbuminemia e com antecedentes de insuficiência renal.
Recomenda-se that bone born of creatinina sejam monitorizados durante bones very primeiros meses de tratamento após o início do tratamento e from daí periodicamente (para recomendações da dose.
Recomenda-uma monitorização dos níveis das transaminases of 3 em 3 meses durante os primeiros doze meses de tratamento e from daí periodic.